INTRODUCTION
Traditionally renal tumours were managed based on radiological characteristics.
Sampling of the renal tumor by biopsy was not considered except in case of suspicion of metastasis from other primary cancers, infectious disease or metastatic disease.
However a considerable amount of new discovered renal tumours is small (≤ 4 cm of maximal diameter). Up to 20% of these small renal masses (SRM) appear to be benign and 60% are low grade RCCs [1] . Although EAU and AUA guidelines do not support the systematic diagnostic use of RMB in suspicion of RCC, they advise this practice in specific situations (e.g. before ablation or to guide the choice of therapy in metastatic RCC) [2;3] . Furthermore a renewed interest in the subject becomes apparent from the increasing literature around the subject (157 publications in the period 1991 to 2001 and 333 from 2001 to 2011 (Pubmed search; all hits revealed using MeSH-term "Renal cell carcinoma" and "biopsy" in title/abstract). Recently numerous publications and several reviews on renal mass biopsies (RMB) have shown a good accuracy and low complication rates [4] [5] [6] [7] [8] .
Nevertheless increased literature diffusion may not necessarily reflect changes in clinical practice since new diagnostic methods require occasionally several years before they are fully implemented in current practice [9] . In the previous decade, two surveys exploring the role of RMB in the medical practice [10;11] showed that RMB was scarcely performed. The primary objective of the current study is to assess the use of renal mass biopsy in the current urological practice. Secondary objective is to assess related factors such as indications and patterns in practice.
METHODS
An electronic survey was generated (www.surveymonkey.com) and distributed through the office of the Endourological society by e-mail blast (see appendix 1). Three e-mails (one initial and two reminders) containing a link to the electronic survey were sent between November 4 th and December 8 th 2010 to all known e-mail addresses of the Endourological Society members (1854 individuals).
The questionnaire contained 6 epidemiological questions, 10 questions regarding patterns of practice, one question regarding the influence of literature revival on the subject and one question on new diagnostic techniques. The question types used were multiple choice and rating scale questions. Based on previous answers non-applicable questions were automatically omitted.
Statistical analysis
Analysis was performed based on the result overviews provided by the Surveymonkeywebsite. Subsequent statistical analysis was carried out in close collaboration with the biostatistical department of our institution and using Predictive Analytics SoftWare (PASW) 18.0.2. The Pearson chi-square test was applied on cross tables to assess unequal distribution of answers between the different groups of responders. To assess differences between specific groups of responders individually, the cross tables were In rare cases 60%
In up to 25% of cases 18%
In up to 50% of cases 4%
In up to 75% of cases 3%
In 100% of cases 2%
"What type of biopsy do you perform?"
Histological biopsy (core biopsy) 61%
Cytological puncture (FNA) 8%
Both histological and cytological puncture 31%
Other <1%
"Who performs the biopsy?"
Radiologist 78%
Urologist 21%
Pathologist <1%
Other 0
Core biopsy: Type of needle

Manual needle 25%
Automatic firing gun 75% 
RESULTS
In total 190 of the 1854 individuals responded resulting in a response rate of 10.2%.
Demographic data
Demographic data is displayed in table 1. Responders were urologists with a median of 10 years since registration (0-45). The majority of the responders practiced in NorthAmerica (57%) and 72% in training hospitals (57% university-and 15% non-university training hospitals). 87% of responders practiced in either North-America, Europe or Asia.
Patterns in practice.
The majority of responders (73%) never or rarely take biopsies and only 9% of the responders take biopsies in more than 25% of cases ( Table 2 ).
Of the responders that indicated to perform RMB, 61% performs only histological (core) biopsies whereas 31% performs both histological biopsy and cytological punctures ( Table 2) .
Biopsies are mainly performed by radiologists and with a 18 G needle (78% and 62% respectively) and CT-scan is the guidance modality of preference (62%), followed by ultrasound (37%). 78% reported never to use MRI for guidance. Table 3a shows the distribution of biopsy rate over the different types of practice. Pearson chi-square shows an unequal distribution over the different types of practice (p<0.001).
Subdividing the results in 4x2 cross tables shows that there are differences in the 
Indications for RMB
Indications to either perform or to refrain from RMB are best displayed in figure 1.
DISCUSSION
Our electronic survey distributed to members of the Endourological Society demonstrates that only a minority of urologists takes RMB regularly.
Patterns in practice
Results on biopsy diffusion should be compared with previous surveys [10;11] Comparison of such characteristics with the survey of Khan et al. is hindered since the presentation of questions was different [10] .
The number of responders that "never take a RMB" decreased from 56% -43% in 2005
(both previous surveys were conducted in 2005) to 13% in the current survey with a linear trend to increasing penetration in clinical practice (table 5) . Nevertheless the real impact of RMB in the diagnostic process of renal masses remains low with only 9% of the responders taking biopsies in at least 50% of cases. These figures do not reflect the significant growth of publications in the last years. The discrepancy between literature diffusion and effective implementation in clinical practice is a well-known phenomenon and rather than physicians alone the organization of care, resources, leadership and social environment are the main causes delaying implementation [9] .
The type of practice does not seem to influence the frequency in performing a biopsy.
Comparison of the different types showed differences among all of them except between non-universitary and private practice. While these data suggest a difference in the biopsy frequency between universitary hospitals and all other types of practice, a trend could not been proven towards higher frequency in any of the practice types in the current survey. Nevertheless there was a significant difference in the rate of responders that "never" perform a biopsy between the university hospitals and the non-university hospitals. This figure may indicate that biopsy police is more liberal in university settings were the influence of recent literature or study purposes are higher than in private or non-training sectors.
Histological biopsy (CB) is preferred over cytological aspiration (FNA) although 1/3 of the responders combine both. Overall 40% of the responders use FNA, a fair increase with respect to the 2005 survey [11] (table 5) . This might be explained by encouraging reports on FNA accuracy in determining biology and subtype and high interobserver concordance as well as implementation of ancillary cytopathological techniques [4;8;12;13] . Furthermore combination of both types of biopsies improves the accuracy of the test including subtype and grade [14] [15] [16] . The majority of the biopsies are taken by radiologists and in most than half of the cases the 18G needle is referred over other calibres.
Rationale for biopsy
For almost 40% of the responders the main reason to perform a biopsy is a solitary kidney followed by tumor in transplant kidney, metastatic RCC, bilateral tumor or 118 presence of co-morbidity and tumor categorized as SRM. These figures fully reproduce the results of a previous survey where the presence of a tumor in a solitary kidney or bilateral tumors were the most important indications to perform a biopsy [10] . While no overall changes in attitude could be recorded, the present survey underscores that biopsy is increasingly considered in case of metastatic RCC, from 29% of responders taking a biopsy in 2007 to 65% indicating in the current survey that this is the most/ moderate important reason. However as far as this indication is concerned the physician has to be aware that a high accuracy in subtype determination is needed as this will drive the choice of systemic therapy (13) . The recent reported lower accuracy of the RMB in those large and heterogeneous metastatic renal masses may hinder the usefulness of RMB in this particular setting [17] .
The presence of a SRM was not among the most important reasons to perform a biopsy in our survey. Around 50% of the responders indicated that a small tumor size 
Limitations
The response rate in our survey might be considered as a major limitation. Several factors can explain the lower response rate compared to the 64% [10] and 22.2% [11] of the previous surveys. Firstly, the current survey was sent to all the e-mail addresses of members of the Endourological Society (EUS), regardless of their field of interest or their type of practice. It is likely to assume that members of the EUS not involved in treatment of renal tumors are less willing to respond to the current survey. Furthermore it is possible that a part of the e-mail addresses was outdated and therefore the message never reached those recipients. Lastly it is well known that postal or locally distributed surveys such as the previous two generate a higher response rate compared to a web-based survey with e-mail announcements [21] .
However when compared to other surveys, the current study is standing out due to the fact that it is fully focussed on RMB and contains a comprehensive set of questions addressing multiple aspects of the matter. Furthermore it was distributed by a professional society with an own target population and preparation and implementation of the study was done completely independent without any support from third parties such as commercial companies. Before distribution a pilot version of the study was tested by several senior and junior urologists both in the Netherlands and in the USA for ease of use and linguistics.
CONCLUSION
Despite the relatively low response rate when comparing with other studies, the current survey suggests that there is a significant decrease in the rate of responders indicating "never to take biopsy". However the real impact of RMB in the pre-operative workup of renal masses remains still low . Main reasons to perform RMB did not change mainly apart from a clear increase in the rate of responders taking biopsy in case of metastatic RCC. SRM alone is not considered an important reason to perform RMB. The use of FNA has increased in the last years, particularly in combination with core biopsy.
